Your browser doesn't support javascript.
loading
Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells.
De Ravin, Suk See; Brault, Julie; Meis, Ronald J; Liu, Siyuan; Li, Linhong; Pavel-Dinu, Mara; Lazzarotto, Cicera R; Liu, Taylor; Koontz, Sherry M; Choi, Uimook; Sweeney, Colin L; Theobald, Narda; Lee, GaHyun; Clark, Aaron B; Burkett, Sandra S; Kleinstiver, Benjamin P; Porteus, Matthew H; Tsai, Shengdar; Kuhns, Douglas B; Dahl, Gary A; Headey, Stephen; Wu, Xiaolin; Malech, Harry L.
Afiliação
  • De Ravin SS; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Brault J; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Meis RJ; CELLSCRIPT, LLC, Madison, WI.
  • Liu S; Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick, MD.
  • Li L; MaxCyte Inc., Gaithersburg, MD.
  • Pavel-Dinu M; Department of Pediatrics, Stanford University, School of Medicine, Stanford, CA.
  • Lazzarotto CR; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
  • Liu T; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Koontz SM; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Choi U; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Sweeney CL; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Theobald N; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Lee G; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
  • Clark AB; Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick, MD.
  • Burkett SS; Molecular Cytogenetic Core Facility, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD.
  • Kleinstiver BP; Center for Genomic Medicine and Department of Pathology, Massachusetts General Hospital, Boston, MA.
  • Porteus MH; Department of Pathology, Harvard Medical School, Boston, MA; and.
  • Tsai S; Department of Pediatrics, Stanford University, School of Medicine, Stanford, CA.
  • Kuhns DB; Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN.
  • Dahl GA; Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Headey S; CELLSCRIPT, LLC, Madison, WI.
  • Wu X; School of Science, RMIT University, Melbourne, VIC, Australia.
  • Malech HL; Cancer Research Technology Program, Leidos Biomedical Research Inc., Frederick, MD.
Blood ; 137(19): 2598-2608, 2021 05 13.
Article em En | MEDLINE | ID: mdl-33623984
ABSTRACT
Lentivector gene therapy for X-linked chronic granulomatous disease (X-CGD) has proven to be a viable approach, but random vector integration and subnormal protein production from exogenous promoters in transduced cells remain concerning for long-term safety and efficacy. A previous genome editing-based approach using Streptococcus pyogenes Cas9 mRNA and an oligodeoxynucleotide donor to repair genetic mutations showed the capability to restore physiological protein expression but lacked sufficient efficiency in quiescent CD34+ hematopoietic cells for clinical translation. Here, we report that transient inhibition of p53-binding protein 1 (53BP1) significantly increased (2.3-fold) long-term homology-directed repair to achieve highly efficient (80% gp91phox+ cells compared with healthy donor control subjects) long-term correction of X-CGD CD34+ cells.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Genética / Transplante de Células-Tronco Hematopoéticas / Reparo do DNA / Proteína 1 de Ligação à Proteína Supressora de Tumor p53 / Edição de Genes / NADPH Oxidase 2 / Doença Granulomatosa Crônica Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Terapia Genética / Transplante de Células-Tronco Hematopoéticas / Reparo do DNA / Proteína 1 de Ligação à Proteína Supressora de Tumor p53 / Edição de Genes / NADPH Oxidase 2 / Doença Granulomatosa Crônica Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article